V
LIVE

Serial Number

98210542

Owner

Belgian Volition SRL

Attorney

Amanda G. Hyland

Filing Date

Oct 5, 2023

Add to watchlist:

No watchlists yet
View on USPTO

V Trademark

Serial Number: 98210542

V is a trademark filed by Belgian Volition SRL on October 5, 2023. The trademark is classified under Class 1 (Chemicals), Class 10 (Medical Apparatus), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Belgian Volition SRL (3 trademarks)

9-13 St. Andrews Street
London EC4A3AF , th

Entity Type: 99

Trademark Details

Filing Date

October 5, 2023

Registration Date

Not Registered

Goods & Services

Medical services and veterinary services; diagnostic medical testing and treatment of disorders, namely, cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, and disorders associated with neutrophil extracellular traps (NETs); medical analysis services relating to the treatment of persons and animals; health care; hospital services; Veterinary services, namely, advisory of medical, diagnostic or surgical services for animals; human tissue bank services; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical clinic services; medical screening; medical equipment rental; epigenetic testing for medical purposes, namely, for diagnosing disease, monitoring disease and treatment efficacy; medical analysis for the diagnosis and treatment of persons and animals; Medical and health care services in the field of DNA, genetics and genetic testing; genetic testing of animals for diagnostic or treatment purposes; DNA and RNA analysis services for medical purposes in the field of cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); Medical diagnosis and prognosis in the field of diseases related to epigenetic and nucleosomal changes, namely cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); genetic testing for medical purposes; Blood analysis services for diagnostic purposes provided by medical laboratories; Veterinary analysis services for diagnostic and treatment purposes provided by veterinary laboratories

Chemicals and biological preparations used in industry and science; chemical and biological reagents for use in industry and science; diagnostic reagents for scientific and research purposes; chemical and biological preparations and reagents for use in diagnostic and analytical tests, including in vitro diagnostic laboratory tests, for scientific purposes and not for medical or veterinary purposes; Reagents for scientific use in the field of life sciences; Active chemical ingredients for use in the manufacture of pharmaceuticals for treating cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); assays for testing stem cell differentiation status, other than for medical or veterinary use

Medical and therapeutic apparatus and instruments for use in treatment of cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS) in humans and animals; Medical and veterinary devices for diagnosing cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs) pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); Medical diagnostic apparatus for analyzing and measuring cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); medical apparatus, instruments and equipment for use in the diagnosis, monitoring and treatment of cancer; medical apparatus, instruments and equipment for use in the monitoring and diagnosis of sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage and inflammation, disorders associated with neutrophil extracellular traps (NETs) and pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); medical apparatus, instruments and equipment for use in monitoring the immune system, namely, for monitoring blood properties; Medical diagnostic apparatus for testing for cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); Medical diagnostic apparatus for use with chemical and biological reagents, for testing for cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); Medical apparatus for use in carrying out diagnostic assays; Medical apparatus, equipment and instruments for monitoring diseases namely, cancer sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); apparatus for DNA and RNA testing for medical purposes; Medical apparatus for use in regeneration of transplant tissues and organs; blood testing apparatus; dialyzers; apheresis devices for medical use; structural parts for all the aforesaid goods

Filing History

NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 27, 2026 GNRN
NON-FINAL ACTION E-MAILED
Apr 27, 2026 GNRT
NON-FINAL ACTION WRITTEN
Apr 27, 2026 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 2, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 2, 2026 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Apr 2, 2026 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 12, 2026 GNFN
FINAL REFUSAL E-MAILED
Jan 12, 2026 GNFR
FINAL REFUSAL WRITTEN
Jan 12, 2026 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 12, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 12, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 12, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 6, 2025 GNRN
NON-FINAL ACTION E-MAILED
Oct 6, 2025 GNRT
NON-FINAL ACTION WRITTEN
Oct 6, 2025 CNRT
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jul 15, 2025 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jan 14, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Jan 14, 2025 GNSL
SUSPENSION LETTER WRITTEN
Jan 14, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 2, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 2, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 2, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Sep 11, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Sep 11, 2024 XELR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 4, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 4, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 4, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sep 4, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sep 4, 2024 COAR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 24, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jun 24, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jun 24, 2024 CNRT
ASSIGNED TO EXAMINER
May 23, 2024 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Oct 14, 2023 MDSM
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 13, 2023 NWOS
NEW APPLICATION ENTERED
Oct 9, 2023 NWAP